Moleculin Biotech (NASDAQ:MBRX) Receives “Buy” Rating from HC Wainwright

Moleculin Biotech (NASDAQ:MBRX)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $22.00 target price on the stock.

Several other analysts have also recently issued reports on MBRX. Roth Mkm reaffirmed a “buy” rating on shares of Moleculin Biotech in a report on Monday, December 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $61.00.

Moleculin Biotech Trading Up 0.7%

Shares of NASDAQ:MBRX traded up $0.02 during mid-day trading on Tuesday, reaching $2.12. The stock had a trading volume of 12,259 shares, compared to its average volume of 174,417. The business’s 50 day moving average price is $3.37 and its 200 day moving average price is $6.99. Moleculin Biotech has a 1 year low of $1.79 and a 1 year high of $33.00. The company has a market cap of $4.31 million, a P/E ratio of -0.06 and a beta of 1.73.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.